PD-L1 expression in gastroesophageal dysplastic lesions.

Autor: Fassan M; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy. matteo.fassan@unipd.it., Brignola S; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Pennelli G; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Alberti G; Unit of Medical Oncology 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy.; Department of Oncology, Surgery and Gastroenterology (DISCOG), University of Padua, Padua, PD, Italy., Angerilli V; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Bressan A; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Pellino A; Unit of Medical Oncology 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy., Lanza C; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Salmaso R; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy., Lonardi S; Unit of Medical Oncology 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy., Pucciarelli S; 1st Surgery Unit, Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy., Spolverato G; 1st Surgery Unit, Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, Italy., Scarpa M; Surgery Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy., Realdon S; Gastroenterology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy., Farinati F; Gastroenterology Unit, Department of Surgical Oncology and Gastroenterology (DiSCOG), University of Padua, Padua, PD, Italy., Luchini C; Section of Pathology, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., Rugge M; Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, via Gabelli 61, 35121, Padua, PD, Italy.; Veneto Cancer Registry, Padua, Italy., Loupakis F; Unit of Medical Oncology 1, Department of Oncology, Istituto Oncologico Veneto, IOV-IRCCS, Padua, PD, Italy.
Jazyk: angličtina
Zdroj: Virchows Archiv : an international journal of pathology [Virchows Arch] 2020 Jul; Vol. 477 (1), pp. 151-156. Date of Electronic Publication: 2019 Nov 14.
DOI: 10.1007/s00428-019-02693-8
Abstrakt: Immunotherapy has been recently approved for gastric (GC) and gastroesophageal-junction adenocarcinomas (GEC), and PD-L1 immunohistochemical evaluation represents a promising predictive biomarker in this oncological setting. A series of 125 gastroesophageal dysplastic lesions (52 low-grade, 73 high-grade) was investigated for PD-L1 and DNA mismatch repair proteins status. PD-L1 was positive (combined positive score (CPS) ≥ 1) in 48 (31.0%) dysplastic lesions. A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028). For 30 dysplastic samples, a synchronous matched invasive lesion (GC = 15, GEC = 15) was available and tested for PD-L1 expression; a discordant PD-L1 status was observed in 12/30 (40%) cases. A relatively high prevalence in PD-L1 positivity was observed among gastroesophageal dysplastic lesions and this should be taken into consideration for future therapeutic strategies based on this biomarker.
Databáze: MEDLINE
Externí odkaz: